Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.17 - $1.92 $115,380 - $189,342
98,616 Added 89.1%
209,298 $332,000
Q4 2023

Feb 13, 2024

SELL
$0.6 - $1.31 $97,607 - $213,109
-162,679 Reduced 59.51%
110,682 $95,000
Q3 2023

May 14, 2024

BUY
$1.05 - $3.37 $170,812 - $548,228
162,679 Added 146.98%
273,361 $292,000
Q3 2023

Nov 14, 2023

BUY
$1.05 - $3.37 $38,456 - $123,426
36,625 Added 15.47%
273,361 $292,000
Q2 2023

May 14, 2024

BUY
$2.44 - $4.53 $112,076 - $208,076
45,933 Added 24.07%
236,736 $613,000
Q2 2023

Aug 14, 2023

BUY
$2.44 - $4.53 $112,076 - $208,076
45,933 Added 24.07%
236,736 $613,000
Q1 2023

May 14, 2024

SELL
$3.72 - $5.4 $702,540 - $1.02 Million
-188,855 Reduced 49.74%
190,803 $778,000
Q1 2023

May 11, 2023

SELL
$3.72 - $5.4 $702,540 - $1.02 Million
-188,855 Reduced 49.74%
190,803 $778,000
Q4 2022

May 14, 2024

BUY
$3.41 - $12.93 $156,924 - $595,025
46,019 Added 13.79%
379,658 $1.91 Million
Q4 2022

Feb 13, 2023

BUY
$3.41 - $12.93 $156,924 - $595,025
46,019 Added 13.79%
379,658 $1.91 Million
Q3 2022

May 14, 2024

BUY
$12.59 - $17.67 $2.03 Million - $2.85 Million
161,433 Added 93.74%
333,639 $4.36 Million
Q3 2022

Nov 10, 2022

BUY
$12.59 - $17.67 $2.03 Million - $2.85 Million
161,433 Added 93.74%
333,639 $4.36 Million
Q2 2022

May 14, 2024

BUY
$10.58 - $17.5 $650,923 - $1.08 Million
61,524 Added 55.59%
172,206 $2.21 Million
Q2 2022

Aug 15, 2022

BUY
$10.58 - $17.5 $87,687 - $145,040
8,288 Added 5.06%
172,206 $2.21 Million
Q1 2022

May 16, 2022

SELL
$13.81 - $18.6 $592,393 - $797,865
-42,896 Reduced 20.74%
163,918 $2.5 Million
Q4 2021

Feb 14, 2022

SELL
$17.26 - $22.02 $771,021 - $983,655
-44,671 Reduced 17.76%
206,814 $3.66 Million
Q3 2021

Nov 10, 2021

BUY
$20.15 - $26.19 $5.07 Million - $6.59 Million
251,485 New
251,485 $5.29 Million

Others Institutions Holding NGM

About NGM BIOPHARMACEUTICALS INC


  • Ticker NGM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,365,904
  • Description
  • NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...
More about NGM
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.